"A PHASE II, RANDOMIZED, OPEN-LABEL, MULTI-CENTER, GLOBAL STUDY OF MEDI4736 MONOTHERAPY, TREMELIMUMAB MONOTHERAPY, AND MEDI4736 IN COMBINATION WITH TREMELIMUMAB IN PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)."
- Registry ID
- D4193C00003
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- ASTRAZENECA AB
- Start date
- 2015-11-02
- Last update
- 2015-05-04
Conditions
- CARCINOMA OF THE HEAD AND NECK
- SQUAMOUS CELL CARCINOMA
Related clinical trials
- A PHASE 1 FIRST-IN-HUMAN, OPEN-LABEL STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF ABBV-711 AS A MONOTHERAPY OR IN COMBINATION WITH BUDIGALIMAB (ABBV-181) IN ADULT SUBJECTS WITH ADVANCED SQUAMOUS TUMORS
- RANDOMIZED PHASE III TRIAL OF NEOADJUVANT IMMUNOTHERAPY WITH RESPONSE ADAPTED TREATMENT VERSUS STANDARD-OF-CARE TREATMENT FOR RESECTABLE STAGE
III/IV CUTANEOUS SQUAMOUS CELL CARCINOMA
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 2/3 STUDY OF FICERAFUSP ALFA
(BCA101) OR PLACEBO IN COMBINATION WITH PEMBROLIZUMAB FOR FIRST LINE
TREATMENT OF PD-L1-POSITIVE, RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS
CELL CARCINOMA
- A PHASE 2/3, ADAPTIVE, RANDOMIZED, OPEN-LABEL, CLINICAL STUDY TO EVALUATE NEOADJUVANT
AND ADJUVANT V940 (MRNA-4157) IN COMBINATION WITH PEMBROLIZUMAB (MK-3475)
VERSUS STANDARD OF CARE, AND PEMBROLIZUMAB MONOTHERAPY IN PARTICIPANTS WITH
RESECTABLE LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA (LA CSCC)
(INTERPATH-007)
- A RANDOMIZED, PHASE 2, OPEN-LABEL, MULTI-ARM STUDY OF TISLELIZUMAB IN
COMBINATION WITH INVESTIGATIONAL AGENTS AS FIRST-LINE TREATMENT IN PATIENTS
WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
- NEOADJUVANT CHEMORADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA VERSUS DEFINITIVE CHEMORADIOTHERAPY WITH SALVAGE SURGERY AS NEEDED(NEEDS TRIAL)
View on source registry